HCmed Innovations Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	100.23	141.61	9.24	6.48	54.06
Revenue Growth (YoY)	-29.22%	1433.43%	42.56%	-88.02%	67.23%
Cost of Revenue	75.31	41.96	35.38	37.25	19.41
Gross Profit	24.92	99.65	-26.15	-30.77	34.65
Selling, General & Admin	79.28	63.91	49.94	48.38	20.75
Research & Development	65.29	73.34	67.67	66.85	43.31
Amortization of Goodwill & Intangibles	-	-	-	-	11.45
Operating Expenses	144.61	137.24	117.61	115.24	75.51
Operating Income	-119.69	-37.59	-143.76	-146	-40.87
Interest Expense	-1.53	-0.24	-0.29	-0.06	-0.05
Interest & Investment Income	3.28	2.48	0.83	0.32	0.19
Earnings From Equity Investments	-	-	-	-0.19	-1.57
Currency Exchange Gain (Loss)	1.03	1.44	0.01	0.24	-0.38
Other Non Operating Income (Expenses)	0.01	0.05	0.15	0.04	0.06
EBT Excluding Unusual Items	-116.89	-33.86	-143.07	-145.65	-42.62
Impairment of Goodwill	-	-12.16	-23.33	-	-
Gain (Loss) on Sale of Investments	-	-	-	1.63	-
Asset Writedown	-11.86	-4.91	-	-	-
Other Unusual Items	0.02	-	-	-	2.43
Pretax Income	-128.73	-50.93	-166.4	-144.03	-40.19
Income Tax Expense	-2.62	27.29	-0.47	-0.24	-
Net Income	-126.11	-78.21	-165.93	-143.79	-40.19
Net Income to Common	-126.11	-78.21	-165.93	-143.79	-40.19
Shares Outstanding (Basic)	32	30	27	22	18
Shares Outstanding (Diluted)	32	30	27	22	18
Shares Change (YoY)	7.03%	13.06%	23.01%	23.04%	0.63%
EPS (Basic)	-3.92	-2.60	-6.25	-6.66	-2.29
EPS (Diluted)	-3.92	-2.60	-6.25	-6.66	-2.29
Free Cash Flow	-124.2	-43.38	-127.74	-87.95	-19.82
Free Cash Flow Per Share	-3.86	-1.44	-4.81	-4.07	-1.13
Gross Margin	24.86%	70.37%	-283.14%	-	64.10%
Operating Margin	-119.41%	-26.55%	-1556.70%	-2253.83%	-75.60%
Profit Margin	-125.82%	-55.23%	-1796.71%	-2219.67%	-74.34%
Free Cash Flow Margin	-123.91%	-30.63%	-1383.17%	-1357.64%	-36.67%
EBITDA	-109.17	-27.11	-132.84	-138.36	-37.17
EBITDA Margin	-108.92%	-19.15%	-	-	-68.76%
D&A For EBITDA	10.52	10.48	10.92	7.64	3.7
EBIT	-119.69	-37.59	-143.76	-146	-40.87
EBIT Margin	-119.41%	-26.55%	-	-	-75.60%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.